The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Don Creighton
Advertisement
Articles by Don Creighton
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
The Variety of Migraine Treatment Options Opens the Door for Pharmacy Services | NCPA 2025
2
Severe COVID-19 Increases Stroke Risk for Patients With Asthma
3
How Community Pharmacists Are Proactively Managing Patients’ Migraines | NCPA 2025
4
Guidelines Are Key for Treating Substance Use Disorder
5
